Fredun Pharma Q1 FY27 Earnings Call — Analysis (NSE: FREDUN)
Fredun Pharma Q1 FY27 revenue surges 90% YoY to ₹228 Cr with EBITDA margin expansion, management outlines 30-35% blended growth trajectory
Result quality: stable — Steady quarter. Management sentiment: optimistic.
The take
Q1FY27 Standalone Total Income ₹228.25 Cr ( +90.44% YoY ) .
Results
Standalone total income ₹228.25 Cr (+90.44% YoY), EBITDA ₹32.78 Cr (+92.90% YoY), EBITDA margin 14.36% (+18 bps), net profit ₹13.17 Cr (+94.63% YoY)
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Standalone Total Income | ₹228.25 Cr | +90.44% | yoy · Q1FY27 |
| EBITDA | ₹32.78 Cr | +92.90% | yoy · Q1FY27 |
| EBITDA Margin | 14.36% | +18 bps | yoy · Q1FY27 |
| Net Profit | ₹13.17 Cr | +94.63% | yoy · Q1FY27 |
| Net Profit Margin | 5.77% | +12 bps | yoy · Q1FY27 |
Guidance
FY27 revenue target ~₹800 Cr with possible over-achievement; blended growth of 30-35% next 3 years; capex ₹35-45 Cr each for FY27-28
What management committed to
- [Fredun Pharmaceuticals] expects blended growth of somewhere around 35% to 30% for the next 3 years, combining all new brands, existing ones, and increased capacities. — 35% to 30% blended annual growth, FY30
- [Fredun GX] expects 25% to 35% growth year-on-year for the next 5 years, due to small base and market potential. — 25% to 35% YoY growth, FY32
- [Fredun Pharmaceuticals] plans CapEx of about INR30 crores to INR40 crores this financial year, and same for next year. — INR30-40 crores per year, FY27 and FY28
- [Wagr.in] will have all major pet care brands onboarded within 20-25 days, and full campaigns and partnerships within 90 days. — all major brands onboarded in 20-25 days; campaigns in 90 days, Q2 FY27
- [Pet care division] expects 40% to 50% growth per year for the next 3 to 4 years, from a small base of INR40-45 crores. — 40% to 50% annual growth, FY30-FY31
- [Fredun Pharmaceuticals] expects operating margins to reach around 12% to 13% within the next 12 quarters (roughly 3 years). — 12% to 13% EBIT margin, Q4 FY30 or earlier
Key themes
New-age brand hypergrowth and pet-care ecosystem building
Operational commentary
- Wagr.in pet parenting platform soft-launched in beta in June 2026; onboarding brands, pharmacies, breeders, trainers, groomers, veterinarians, and diagnostics; full public launch expected in 60-90 days.
- Fredun GX now present in 19 states; deeper penetration into Tier 2-4 cities driving growth; revenue base ~₹110 Cr with 25-35% annual growth target.
- Pet care diagnostic centres: first centre in Mumbai (Worli) operational; additional centres in Malad and Vashi under development.
- Functional foods expanded to 42 variants; Jain variant gaining strong traction; cat biscuit treats launching in 6-7 months; cat food launch planned by Q4 FY27.
- Manufacturing capacity expansion underway to become one of the largest single-location pharma manufacturing units by end-2028/early-2029; 5 plants in Palghar, 43 manufacturing locations.
- Credit rating upgraded from BBB to BBB+, contributing to lower interest costs.
- All business divisions now headed by separate CEOs with industry stalwarts; extremely low employee attrition.
Analyst Q&A
Q. Can we target revenue of ₹1,000 Cr and EBIT of ₹100 Cr this year?
No commitment given; FY27 target was ₹800 Cr, we may overachieve but will not promise ₹1,000 Cr. For EBIT margin of 12-13%, it could happen within ~12 quarters but no fixed month.
Research and educational content only. Not investment advice.